Attached files

file filename
10-K - FORM 10-K - CTI BIOPHARMA CORPd10k.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-23.2 - CONSENT OF MARCUM LLP - CTI BIOPHARMA CORPdex232.htm
EX-23.1 - CONSENT OF STONEFIELD JOSEPHSON, INC. - CTI BIOPHARMA CORPdex231.htm
EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - CTI BIOPHARMA CORPdex121.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - CTI BIOPHARMA CORPdex211.htm
EX-10.24 - FORM OF AMENDMENT TO AMENDMENT TO EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT - CTI BIOPHARMA CORPdex1024.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm

EXHIBIT 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Cell Therapeutics, Inc. on Form 10-K for the fiscal year ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.

A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: February 16, 2011

     By:     

/s/ James A. Bianco

     James A. Bianco, M.D.
     Chief Executive Officer

I, Louis A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Cell Therapeutics, Inc. on Form 10-K for the fiscal year ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.

A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

Dated: February 16, 2011

     By:     

/s/ Louis A. Bianco

     Louis A. Bianco
     Executive Vice President
     Finance and Administration